Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 22, 2017
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and fifty-three approved drugs.| International Patents: | 1782 |
| US Patents: | 58 |
| Tradenames: | 120 |
| Ingredients: | 106 |
| NDAs: | 153 |
| Drug Master File Entries: (click here to view) | 3 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
tofacitinib | Extended-release Tablets | 11 mg | XELJANZ XR | 11/7/2016 |
ibuprofen and diphenhydramine citrate | Capsules | 200 mg/38 mg | ADVIL PM | 2/16/2016 |
dofetilide | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | TIKOSYN | 5/1/2014 |
fesoterodine fumarate | Extended-release Tablets | 4 mg and 8 mg | TOVIAZ | 10/31/2012 |
nitroglycerin | Sublingual Tablets | 0.6 mg | NITROSTAT | 12/29/2011 |
azithromycin | For Injection | 500 mg/vial | ZITHROMAX | 6/17/2011 |
varenicline tartrate | Tablets | 0.5 mg and 1 mg | CHANTIX | 5/10/2010 |
eletriptan hydrobromide | Tablets | 20 mg and 40 mg | RELPAX | 3/29/2010 |
amlodipine besylate and atorvastatin calcium | Tablets | 2.5 mg/40 mg | CADUET | 9/17/2009 |
amlodipine besylate and atorvastatin calcium | Tablets | 5 mg/80 mg | CADUET | 4/7/2009 |
amlodipine besylate and atorvastatin calcium | Tablets | 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg | CADUET | 12/29/2006 |
sertraline hydrochloride | Tablets | 150 mg and 200 mg | ZOLOFT | 11/9/2005 |
nitroglycerin | Sublingual Tablets | 0.3 mg, 0.4 mg and 0.6 mg | NITROSTAT | 10/19/2005 |
zaleplon | Capsules | 5 mg and 10 mg | SONATA | 6/21/2005 |
ziprasidone hydrochloride | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | GEODON | 2/7/2005 |
ibuprofen potassium and pseudoephedrine hydrochloride | Capsules | 200 mg/30 mg | ADVIL COLD AND SINUS | 12/27/2004 |
sildenafil citrate | Tablets | 25 mg and 50 mg | VIAGRA | 11/19/2004 |
sildenafil citrate | Tablets | 100 mg | VIAGRA | 10/25/2004 |
irinotecan hydrochloride | Injection | 20 mg/mL, 2 mL and 5 mL vials | CAMPTOSAR | 7/26/2004 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,737,045 | Methods and compositions for the pulmonary delivery insulin | ► Subscribe | |||||||||||||
| 5,458,135 | Method and device for delivering aerosolized medicaments | ► Subscribe | |||||||||||||
| 6,592,904 | Dispersible macromolecule compositions and methods for their preparation and use | ► Subscribe | |||||||||||||
| 6,380,226 | Salts of an anti-migraine indole derivatives | ► Subscribe | |||||||||||||
| 7,951,557 | Human lysosomal proteins from plant cell culture | ► Subscribe | |||||||||||||
| 5,775,320 | Method and device for delivering aerosolized medicaments | ► Subscribe | |||||||||||||
| 9,364,541 | Pharmaceutical compositions comprising Fesoterodine | ► Subscribe | |||||||||||||
| 6,627,754 | Pyrrolo[2,3-d]pyrimidine compounds | ► Subscribe | |||||||||||||
| 7,432,370 | Chiral salt resolution | ► Subscribe | |||||||||||||
| 6,951,938 | Aryl fused azapolycyclic compounds | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 702150 | ► Subscribe | |||||||||||||
| Hungary | 229867 | ► Subscribe | |||||||||||||
| Germany | 69835245 | ► Subscribe | |||||||||||||
| Colombia | 5640087 | ► Subscribe | |||||||||||||
| Australia | 662919 | ► Subscribe | |||||||||||||
| Japan | 3579060 | ► Subscribe | |||||||||||||
| Australia | 2009251081 | ► Subscribe | |||||||||||||
| Germany | 10299004 | ► Subscribe | |||||||||||||
| Austria | 284868 | ► Subscribe | |||||||||||||
| African Intellectual Property Organization (OAPI) | 11946 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00375 | Netherlands | ► Subscribe | PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819 | ||||||||||||
| C0013 | France | ► Subscribe | PRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214 | ||||||||||||
| C/GB11/010 | United Kingdom | ► Subscribe | PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK | ||||||||||||
| 90005 | Netherlands | ► Subscribe | PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622 | ||||||||||||
| 226 | Luxembourg | ► Subscribe | PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121 | ||||||||||||
| C0008 | Belgium | ► Subscribe | PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204 | ||||||||||||
| C0009 | France | ► Subscribe | PRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927 | ||||||||||||
| 0355 | Netherlands | ► Subscribe | 300355, 20181113, EXPIRES: 20220425 | ||||||||||||
| 2017 00030 | Denmark | ► Subscribe | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 | ||||||||||||
| 2014 00050 | Denmark | ► Subscribe | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,997 others who get our Drug Patent Expiration Alerts:
